After Piper Sandler and H.C. Wainwright gave Cytokinetics (NASDAQ: CYTK) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Salim Syed maintained a Buy rating on Cytokinetics today and set a price target of $80.00. The companys shares closed last Friday at $40.35.

According to TipRanks.com, Syed is ranked 0 out of 5 stars with an average return of -15.9% and a 36.2% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $63.82 average price target, a 50.2% upside from current levels. In a report issued on June 17, Piper Sandler also maintained a Buy rating on the stock with a $72.00 price target.

See the top stocks recommended by analysts >> Based on Cytokinetics latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.15 million and GAAP net loss of $89.45 million. In comparison, last year the company earned revenue of $6.55 million and had a GAAP net loss of $47.1 million. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA. Read More on CYTK:

• ARMOUR Residential REIT, Inc. Confirms July 2022 Dividend Rate Per Common Share and Q3 2022 Monthly Dividend Rate Per Series C Preferred Share
• Portillo’s Inc. to Announce Second Quarter 2022 Results on Thursday, August 4, 2022
• Jamf Introduces Jamf Safe Internet to Power Online Safety Anywhere Students Learn
• Check Point Software to Announce Second Quarter 2022 Financial Results on August 1, 2022
• Oaktree Specialty Lending Corporation Schedules Third Fiscal Quarter Earnings Conference Call for August 4, 2022